Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers

Group 1 - Orion's collaborator, MSD, has expanded the clinical development program for opevesostat to include women's cancers, specifically breast, endometrial, and ovarian cancers [1] - A new Phase 2 clinical trial for opevesostat has been posted on ClinicalTrials.gov, although it is not yet recruiting patients [1] - MSD holds global exclusive rights to opevesostat, which is an oral, non-steroidal, and selective inhibitor of CYP11A1 developed by Orion [1] Group 2 - MSD is currently evaluating opevesostat in several clinical trials, including two Phase 3 trials for metastatic castration-resistant prostate cancer [1] - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on human and veterinary pharmaceuticals [2] - In 2024, Orion's net sales amounted to EUR 1,542 million, and the company employed approximately 3,700 professionals worldwide [2]